Malaysia to Enforce Early Drug Shortage Reporting from July 2026 to Strengthen Supply Security
KUALA LUMPUR: Malaysia will require pharmaceutical companies to report potential drug shortages at least six months in advance starting July 1, 2026, as part of a broader effort to enhance preparedness against global supply chain disruptions.
Health Minister Datuk Seri Dr. Dzulkefly Ahmad said the move, currently voluntary, marks a shift toward proactive risk management to ensure uninterrupted access to essential medicines amid ongoing global uncertainties.
Under the new requirement, product registration holders (PRH) must notify authorities of any anticipated supply disruptions or discontinuations through the National Pharmaceutical Regulatory Agency (NPRA).
“This is about early forecasting and warning systems. We are transitioning from reactive management to a proactive risk anticipation approach, and the six-month rule is a key part of that,” he said during Bernama TV’s The Nation program titled “Safeguarding Medical Supplies in Times of Uncertainty.”
Industry players have been given until April 15 to provide feedback on the availability of active pharmaceutical ingredients and packaging materials, enabling early intervention before shortages impact healthcare facilities.
Dzulkefly noted that the policy is part of Malaysia’s long-term strategy to mitigate the effects of global supply chain disruptions, which could persist even after geopolitical crises subside.
The Health Ministry is maintaining a forward-looking strategy through the first quarter of 2027 to strengthen the resilience of the country’s pharmaceutical logistics.
“Supply chain pressures often emerge as after-effects of crises and can last at least six months based on our simulations. Our preparations must therefore be continuous and not dependent on short-term geopolitical changes,” he said.
To boost preparedness, Malaysia is also reinforcing its buffer stock system, maintaining one to three months of supply at healthcare facilities and an additional two-month reserve at the concession level.
The country is diversifying its sources for medicines and medical devices to reduce reliance on a single market. Meanwhile, the Medical Device Authority (MDA) has introduced fast-response mechanisms, including special access pathways for critical equipment during emergencies.
Dzulkefly added that Malaysia is adopting a data-driven approach to stockpiling, balancing preparedness with cost efficiency and minimizing wastage, lessons learned from the COVID-19 pandemic.
“Stockpiling requires significant funding and storage capacity. Our approach is smart, strategic, and prudent, ensuring we have the right items at the right time without unnecessary waste,” he said.
Emergency reserves will only be deployed under specific conditions, such as major supply disruptions, operational delays, or public health crises.
Looking ahead, Dzulkefly said Malaysia is accelerating its transition from a crisis-driven approach to becoming a more self-reliant and sustainable regional player in healthcare manufacturing.
He highlighted the MyMedSecure initiative as a cornerstone policy aimed at strengthening domestic capabilities, including reducing dependence on imports through local production of critical pharmaceutical ingredients and finished products.